Changes to existing prior authorization programs
| Updates to existing prior authorization programs | |||
| Drug | Plan | Eff. date | Policy & additional information |
| Dalfampridine | Tufts Health RITogether | March 1, 2024 | Ampyra (dalfampridine) |
| Firdapse | Tufts Health RITogether | March 1, 2024 | Firdapse |
| Opzelura | Tufts Health RITogether | March 1, 2024 | Opzelura |
| Contrave
Saxenda Wegovy
|
Harvard Pilgrim Health Care commercial, Tufts Health Plan commercial, Tufts Health Direct | March 1, 2024 | Weight Loss Medications (Harvard Pilgrim, Tufts Health Plan) |
| Opioids | Tufts Health Together | March 4, 2024 | Opioids and Analgesics (criteria will be available on the MassHealth Drug List on or after the effective date) |
| Drug status changes | |||
| Drug | Plan | Eff. Date | Policy and Additional Information |
| Vosevi | Tufts Health RITogether | March 1, 2024 | Vosevi will be moved to non-preferred status. Medications for the Treatment of Hepatitis C |
Audrey Kleinberg,
Director, Provider Relations & Communications
Annmarie Dadoly,
Senior Manager, Provider Communications
Joseph O’Riordan, Susan Panos, Ryan Francis, Stephen Wong,
Writers
Kristin Edmonston,
Production Coordinator
Kristina Cicelova,
Graphic Designer